Heart failure with preserved ejection fraction. Can we improve the prognosis of our patients?
DOI:
https://doi.org/10.47196/diab.v56i3Sup.536Keywords:
heart failure, ejection fractionAbstract
HF with preserved EF is defined as HF with left ventricular EF ≥ 50%. Patients with slightly impaired EF, between 41 and 49%, are usually considered together with EF ≥ 50% in randomized studies. Unlike HF with depressed EF (≤40%) in which different interventions (neurohormonal antagonists, electrical therapy) have been shown to improve prognosis, until recently we did not have evidence from a randomized study in the context of EF >40%. Practice guidelines generally recommended evaluating the etiology, considering comorbidities, and controlling accompanying conditions (heart rate, blood pressure, atrial fibrillation, ischemia). In the subgroup of patients with EF between 41% and 49%, there was a IIb indication for neurohormonal antagonists in the 2021 ESC HF guideline. (1)
References
I. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
II. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-1461.
III. Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernández AF et al. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER Trial. JACC Heart Fail 2022;10:184-197.
IV. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:e263-e421.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
